scholarly journals Long-Term Outcomes After Primary Bowel Resection in Pediatric-Onset Crohn’s Disease

2017 ◽  
Vol 24 (1) ◽  
pp. 149-158 ◽  
Author(s):  
Firas Rinawi ◽  
Noam Zevit ◽  
Rami Eliakim ◽  
Yaron Niv ◽  
Raanan Shamir ◽  
...  

Abstract Background There is limited evidence on the long-term outcome of intestinal resection in pediatric-onset Crohn’s disease (POCD) with no established predictors of adverse outcomes. We aimed to investigate clinical outcomes and predictors for adverse outcome following intestinal resection in POCD. Methods The medical records of patients with POCD who underwent at least 1 intestinal resection between 1990 and 2014 were reviewed retrospectively. Main outcome measures included time to first flare, hospitalization, second intestinal resection, and response to nonprophylactic biologic therapy. Results Overall, 121 patients were included. Median follow-up was 6 years (range 1–23.6). One hundred and seven (88%) patients experienced at least 1 postsurgical exacerbation, 52 (43%) were hospitalized, and 17 (14%) underwent second intestinal resection. Of 91 patients who underwent surgery after the year 2000, 37 (41%) were treated with antitumor necrosis factor ɑ (anti-TNFɑ) (nonprophylactic) following intestinal resection. Time to hospitalization and to second intestinal resection were shorter among patients with extraintestinal manifestations (EIMs) (HR 2.7, P = 0.006 and HR = 3.1, P = 0.03, respectively). Time to initiation of biologic treatment was shorter in patients with granulomas (HR 2.1, P = 0.038), whereas being naïve to anti-TNFɑ treatment before surgery was a protective factor for biologic treatment following surgery (HR 0.3, P = 0.005). Undergoing intestinal resection beyond the year 2000 was associated with shorter time to first flare (HR 1.9, P = 0.019) and hospitalization (HR 2.6, P = 0.028). Conclusion Long-term risk for flares, hospitalization, or biologic treatment is significant in POCD following bowel resection. EIMs increase the risk for hospitalization and second intestinal resection.

2008 ◽  
Vol 23 (12) ◽  
pp. 1167-1174 ◽  
Author(s):  
Igors Iesalnieks ◽  
Alexandra Kilger ◽  
Heidi Glaß ◽  
Rene Müller-Wille ◽  
Frank Klebl ◽  
...  

2006 ◽  
Vol 41 (10) ◽  
pp. 1204-1208 ◽  
Author(s):  
Erlend Landsend ◽  
Egil Johnson ◽  
Hans-Olaf Johannessen ◽  
Erik Carlsen

2005 ◽  
Vol 58 (10) ◽  
pp. 885-890 ◽  
Author(s):  
A. Sugita ◽  
H. Kimura ◽  
K. Koganei ◽  
F. Kito ◽  
H. Shimada ◽  
...  

2019 ◽  
Vol 51 (4) ◽  
pp. 496-502 ◽  
Author(s):  
Mathurin Fumery ◽  
Benjamin Pariente ◽  
Helene Sarter ◽  
Guillaume Savoye ◽  
Claire Spyckerelle ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Jian Wan ◽  
Xuan Wang ◽  
Yujie Zhang ◽  
Xianmin Xue ◽  
Yani Li ◽  
...  

Background and Aims. The efficacy of 5-aminosalicylic acid (5-ASA) in the long-term outcome of Crohn’s disease (CD) patients was uncertain. This study aimed to evaluate the efficacy of the 5-ASA in preventing disease behavior progression and intestinal resection in CD patients. Methods. CD patients were prospectively enrolled from January 2008 to September 2019 in Xijing Hospital. Disease behavior progression was defined as the development of stricturing (B2) or penetrating disease (B3) in patients with nonstricturing/nonpenetrating disease (B1) at diagnosis. Cox regression analyses were used to investigate the associations between disease location progression, disease behavior progression, and intestinal resection and multiple covariates. Results. In total, 122 CD patients were followed up for 4.3 years. At the time of diagnosis, disease location was ileal in 19.7% (24/122), colonic in 41.0% (50/122), and ileocolonic in 39.3% (48/122). A total of 87 (71.3%) patients had B1 at diagnosis. The disease behavior progression and intestinal resection rates were 42.5% (37/87) and 29.5% (36/122). The use of 5-ASA reduced the risk of disease behavior progression (HR 0.30, 95% CI 0.14–0.61, P  = 0.001) and intestinal resection (HR 0.33, 95% CI 0.17–0.90, P  = 0.027) in colonic and ileocolonic CD patients. Patients who presented with ileal disease at diagnosis did not have the same protective effects when taking 5-ASA ( P  > 0.05). Conclusions. The use of 5-ASA could improve the long-term outcome of CD patients with colon involvement. The result emphasized the importance of early use of 5-ASA in the daily management of colonic involved CD.


2004 ◽  
Vol 19 (4) ◽  
pp. 427-434 ◽  
Author(s):  
H. H. Wenzl ◽  
T. A. Hinterleitner ◽  
B. W. Aichbichler ◽  
P. Fickert ◽  
W. Petritsch

Sign in / Sign up

Export Citation Format

Share Document